insights_auto
Pse është rritur CRSP 5,85%?
Zhytu më thellëchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
53,39Â US$
arrow_upward
+5,85%(+2,95) 1D
54,10Â US$
arrow_upward
+1,33% (+0,71)bedtimeJashtë orarit
Mbyllur: 9 tet, 4:00:00 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për CRSP...
Hap
50,82Â US$
I lartë
54,07Â US$
I ulët
50,52Â US$
Kapitalizimi i tregut
5,16Â mld
Vëllimi mesatar
1,62Â mln
Vëllimi
1,47Â mln
Maksimumi 52-javor
78,00Â US$
Minimumi 52-javor
44,12Â US$
Fitimet për aksion
-4,76Â US$
Beta
1,45
Aksionet në qarkullim
96,69Â mln
Numri i punonjësve
393
Hap
50,82Â US$
I lartë
54,07Â US$
I ulët
50,52Â US$
Kapitalizimi i tregut
5,16Â mld
Vëllimi mesatar
1,62Â mln
Vëllimi
1,47Â mln
Maksimumi 52-javor
78,00Â US$
Minimumi 52-javor
44,12Â US$
Fitimet për aksion
-4,76Â US$
Beta
1,45
Aksionet në qarkullim
96,69Â mln
Numri i punonjësve
393
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Simply Wall Street
·
23 orë më parë
Upcoming CTX310 Data Could Test The Case For CRISPR Therapeutics Stock
The Motley Fool
·
1 ditë më parë
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
Zacks
·
1 ditë më parë
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
MarketBeat
·
1 ditë më parë
CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Rated "Moderate Buy" by Sell-Side Brokerages
Profili
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Rreth Crispr Therapeutics AG
Drejtori ekzekutivSamarth Kulkarni
Punonjësit393
Themeluar më2013
SeliaZug, Kantoni Zug, Zvicër
Sektori-
Uebsajticrisprtx.com